IDH1 mutation

#ICYMI the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/PDtssjLQyN @OHSUSOM #leuSM (@BCD_AACR)

Our last paper : targeted therapy with ivosidenib for IDH1 mutated intrahepatic cholangiocarcinoma! A further step forward to tailored treatment! @LorenzaRimassa https://t.co/n0z0sVjgRy (@casadei_gardini)

From the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/mwHChay9AJ @OHSUSOM #leuSM (@BCD_AACR)

#ICYMI— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/QqtrVrDF4l @OHSUSOM #leuSM (@BCD_AACR)

A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies— by @CLachowiez et al. https://t.co/p3FEtJd5Jn @OHSUSOM #leuSM (@BCD_AACR)

A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies— by @CLachowiez et al. https://t.co/eCADNqPNTX @OHSUSOM #leuSM (@BCD_AACR)

🔥EMA approves Ivosidenib/Tibsovo for IDH1 mutant #cholangiocarinoma🔥 👉great news for our pts! 👉only 🎯💊with phs-III evidence in BTC 👉the 1st step...now we need to explore more (IO-) combinations @myESMO @OncoAlert @EASLedu @CcaEns #LiverTwitter (@ArndtVogel)

A phase Ib/II #clinicaltrial of #ivosidenib with #venetoclax +/- #azacitidine in IDH1-mutated #myeloidmalignancies, with #clonalevolution tracked by #singlecell #proteogenomics— by @CLachowiez et al. https://t.co/KDts6lTi4N @OHSUSOM #leuSM (@BCD_AACR)

2/ IDH1-mutated myeloid malignancies are more dependent on BCL2 for survival, suggesting the incorporation of VEN may enhance leukemic cell death in this molecular subgroup. (@CLachowiez)

Excited to share our work out in @BCD_AACR, supported by a @ConquerCancerFd YIA evaluating the @MDAndersonNews triplet of IVO+VEN+AZA in IDH1-mutated myeloid malignancies mentored by C. DiNardo @sanamloghavi @DrKTakahashi @mkonople @DrHKantarjian https://t.co/PzQAwY5F1N A 🧵... (@CLachowiez)

7/ We sought to evaluate if the incorporation of IVO with AZA+VEN was safe and active in IDH1-mutated AML, evaluating 4 different dose levels and a variety of myeloid disease types (ND-AML, R/R-AML, high risk MDS or MPN): (@CLachowiez)

4/ Both AZA+VEN and Ivosidenib (IVO)+VEN are effective in IDH1-mutated AML, resulting in prolonged survival: (@CLachowiez)

Excellent news! #CHMP positive opinion for #ivosidenib for #IDH1 mutant #cholangiocarcinoma #CCA @CharityAMMF @CcaEns @CholangioNet @myESMO (@LorenzaRimassa)

#Olutasidenib in patients with #IDH1 mutated #AML and #MDS patients. 👉🏻most patients were IDHi naive Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial https://t.co/mLgovursUE (@AlkaliDr)

Oncology Board Review! A 50 year old with no medical history presents with pancytopenia. A bone marrow biopsy reveals AML with normal cytogenetics. An IDH1 mutation is identified with a high VAF. You recommend for induction??? (@AaronGoodman33)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML | Blood Advances | American Society of Hematology #leusm https://t.co/8jQfyYOFXC (@TaylorJ_MD)

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia by #DrAditiSharma and @a_mangaonkar https://t.co/rt5KQLfwvj @dipeshuprety4 (@BTFCancerNews)

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial #leusm #MDS https://t.co/axSZDll4F0 (@smbenlazar)

The cost effectiveness of a combination therapy for IDH1-mutated acute myeloid leukemia #AML was analyzed in this study with Dr. Amer Zeidan @Dr_AmerZeidan and @YaleHematology colleagues. https://t.co/rkLknR9UM4 @SmilowCancer @YaleMed @YNHH (@YaleCancer)

🔥 session on CH,Aging & Inflammation.Key takeaways:Need better risk scores for CH @Lachelle_Dawn leads the charge with CHRS score-Chemo accelerates CH esp PPM1D/TP53 to cause t-MN-IDH1 mutations in preLSCs can drive CCUS/AML-Canakinumab improves CHIP related anemia @WJanghee (@beatalleukemia)

Breaking News! Another #IDHinhibitor receives #FDAapproval for IDH1-mutated R/R #AML https://t.co/QKh65BANri https://t.co/zRyusbOXuJ (@FilipJankuMD)

#FDA approves olutasidenib for relapsed or refractory AML with a susceptible IDH1 mutation! Previously approved several other for AML and ivosidenib for adv/met cholangiocarcinoma! 🧬Is IDH ready to be tumor agnostic? @US_FDA @OncoAlert @VivekSubbiah https://t.co/353SbGWHqZ (@DrYukselUrun)

$RIGL - Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation https://t.co/hmlgiEm0hi (@PLMcCarthyMD)

T:👉 FDA IDH1 mutasyonu olan nükseden veya dirençli akut miyeloid lösemili (AML) yetişkin hastalar için olutasidenib (Rezlidhia) ilacını onayladı.✅ https://t.co/jVueLYYXop (@ilyassahinMD)

FDA Approves Olutasidenib for IDH1-Mutated Relapsed/Refractory AML| new kid in the block!!! Glad we have one more treatment option #leusm ⁦@JustinWattsMD⁩ ⁦@SylvesterCancer⁩ ⁦@DrSDNimer⁩ https://t.co/XcOjeFwdK6 (@drsangeetmd)

FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation https://t.co/YW9PDFPacB #IDH1inh #leusm (@TalhaBadarMD)

FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation https://t.co/oJBzHcwdcD (@cvigilgonzales)

Vorasidenib, Ivosidenib Show Encouraging Activity in IDH1-Mutant Low-Grade Glioma https://t.co/Utfg9Rv48O via @onclive (@robson_coelho)

Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia https://t.co/V1fZGadcpA #AML #ASH22 (@smbenlazar)

Azacitidine ± Ivosidenib in Untreated IDH1-Mutant #AML: Efficacy (@smbenlazar)

ELN Guidelines: Therapy Options for Patients With IDH1 Mutations Not Suitable for Intensive Chemotherapy #AML (@smbenlazar)

Ivosidenib in IDH1-Mutated R/R #AML: OS (@smbenlazar)

A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation | Science https://t.co/IPTtYyGlZ4 (@weldeiry)

#OpenAccess in @Nature_NPJ #PrecisionOncology - a description on mechanisms of resistance to ivosidenib in two #cancer #patients with IDH1 mutant cholangiocarcinoma. @OncoAlert 🚨#PrecisionMedicine @ArndtVogel https://t.co/H0gspcx31q (@BenWestphalen)

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis @LorenzaRimassa https://t.co/ZlHSC10tVO (@casadei_gardini)

Oncology Board Review A 77 year old male presents with pancytopenia. A bone marrow biopsy is performed and demonstrates AML. NGS reveals an IDH1 mutation. Which of the following regimens is supported by a randomized clinical trial that demonstrates an OS advantage? (@AaronGoodman33)

Ivosidenib resistance in cholangio can be caused by development of a: 1. Oncogenic IDH2 mutation 2. Secondary IDH1 mutation The IDH1 mutation D279N causes ivosidenib resistance by blocking ivosidenib-IDH1 binding. The IDH1 inhibitor LY3410738 can overcome this resistance. (@JamesClearyMD)

Our new paper examines how acquired resistance to ivosidenib develops in #IDH1 mutated #cholangiocarcinoma. Like IDH1 mutated AML, resistance occurs through the development of IDH1/2 mutations that allow continued production of the oncometabolite R-2HG. https://t.co/hAKpJXq2dc (@JamesClearyMD)

Excellent analysis of the some of the issues in this trial by ⁦@AaronGoodman33⁩ and colleagues Ivosidenib and Azacitidine in IDH1-Mutated AML | NEJM https://t.co/szCFrxJsSw (@Dr_AmerZeidan)

Hope this gets approved for IDH1 mutated astrocytoma soon 🤞 (@CancerFinalGirl)

In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2 https://t.co/IalOj0fHUQ (@weldeiry)

Targeting IDH1 mutation in elderly (2) #AML #EHA22 Image (@smbenlazar)